OBJECTIVES: Intestinal alkaline sphingomyelinase, by exerting a major role in dietary sphingomyelin digestion, is responsible for the generation of messengers able to trigger the rapid turnover and apoptosis in intestinal epithelial cells. Markedly reduced mucosal alkaline sphingomyelinase activity has been associated with human colorectal neoplasms. The aim of this study was to analyze the alkaline sphingomyelinase activity in feces from healthy subjects and colorectal adenocarcinoma patients and to correlate it with the enzyme activity in intestinal tissues. MATERIALS AND METHODS: The enzyme activity was measured both in the intestinal samples from 12 healthy controls and 51 patients with colorectal adenocarcinoma (tumoral and paratumoral tissue) and in the fecal samples of 34 healthy subjects and 29 patients with adenocarcinoma. The relation between sphingomyelinase activity and Dukes' stage, cell differentiation degree, age, and gender was also analyzed. RESULTS: Alkaline sphingomyelinase was significantly decreased (P < 0.001; mean reduction >90%) in tumoral intestinal mucosa of patients compared with controls independently of Dukes' stage and tumor differentiation grade. Interestingly, the enzyme activity in histologically normal paratumoral tissues was statistically lower than control samples (P < 0.001). As occurs in neoplastic tissues, a relevant mean reduction (P < 0.0001; almost 90%) of alkaline sphingomyelinase was revealed in stool samples from tumor patients when compared with controls. CONCLUSION: These findings may have implications for cancer biology and perhaps also for the design of clinical test, thus suggesting that the fecal sphingomyelinase activity could really reflect the human intestinal mucosa enzyme level and could represent a new marker for human colorectal adenocarcinoma, mainly taking into account its early appearance in intestinal neoplasms.
OBJECTIVES: Intestinal alkaline sphingomyelinase, by exerting a major role in dietary sphingomyelin digestion, is responsible for the generation of messengers able to trigger the rapid turnover and apoptosis in intestinal epithelial cells. Markedly reduced mucosal alkaline sphingomyelinase activity has been associated with humancolorectal neoplasms. The aim of this study was to analyze the alkaline sphingomyelinase activity in feces from healthy subjects and colorectal adenocarcinomapatients and to correlate it with the enzyme activity in intestinal tissues. MATERIALS AND METHODS: The enzyme activity was measured both in the intestinal samples from 12 healthy controls and 51 patients with colorectal adenocarcinoma (tumoral and paratumoral tissue) and in the fecal samples of 34 healthy subjects and 29 patients with adenocarcinoma. The relation between sphingomyelinase activity and Dukes' stage, cell differentiation degree, age, and gender was also analyzed. RESULTS: Alkaline sphingomyelinase was significantly decreased (P < 0.001; mean reduction >90%) in tumoral intestinal mucosa of patients compared with controls independently of Dukes' stage and tumor differentiation grade. Interestingly, the enzyme activity in histologically normal paratumoral tissues was statistically lower than control samples (P < 0.001). As occurs in neoplastic tissues, a relevant mean reduction (P < 0.0001; almost 90%) of alkaline sphingomyelinase was revealed in stool samples from tumorpatients when compared with controls. CONCLUSION: These findings may have implications for cancer biology and perhaps also for the design of clinical test, thus suggesting that the fecal sphingomyelinase activity could really reflect the human intestinal mucosa enzyme level and could represent a new marker for humancolorectal adenocarcinoma, mainly taking into account its early appearance in intestinal neoplasms.
Authors: James J Goedert; Joshua N Sampson; Steven C Moore; Qian Xiao; Xiaoqin Xiong; Richard B Hayes; Jiyoung Ahn; Jianxin Shi; Rashmi Sinha Journal: Carcinogenesis Date: 2014-07-18 Impact factor: 4.944
Authors: Jun Wu; Ake Nilsson; Bo A G Jönsson; Hanna Stenstad; William Agace; Yajun Cheng; Rui-Dong Duan Journal: Biochem J Date: 2006-02-15 Impact factor: 3.857
Authors: I Soo; K L Madsen; Q Tejpar; B C Sydora; R Sherbaniuk; B Cinque; L Di Marzio; M Grazia Cifone; C Desimone; R N Fedorak Journal: Can J Gastroenterol Date: 2008-03 Impact factor: 3.522
Authors: Caroline B Appleyard; Myrella L Cruz; Angel A Isidro; Janelle C Arthur; Christian Jobin; Claudio De Simone Journal: Am J Physiol Gastrointest Liver Physiol Date: 2011-09-08 Impact factor: 4.052
Authors: Xiaoxiao Li; James LeBlanc; Allison Truong; Ravi Vuthoori; Sharon S Chen; Jonathan L Lustgarten; Bennett Roth; Jeff Allard; Andrew Ippoliti; Laura L Presley; James Borneman; William L Bigbee; Vanathi Gopalakrishnan; Thomas G Graeber; David Elashoff; Jonathan Braun; Lee Goodglick Journal: PLoS One Date: 2011-11-21 Impact factor: 3.240
Authors: Itzhak Avital; Russell C Langan; Thomas A Summers; Scott R Steele; Scott A Waldman; Vadim Backman; Judy Yee; Aviram Nissan; Patrick Young; Craig Womeldorph; Paul Mancusco; Renee Mueller; Khristian Noto; Warren Grundfest; Anton J Bilchik; Mladjan Protic; Martin Daumer; John Eberhardt; Yan Gao Man; Björn Ldm Brücher; Alexander Stojadinovic Journal: J Cancer Date: 2013-03-01 Impact factor: 4.207